Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Quarterly results
Auditor change
Appointed director
Director comp.
Acq. announced
|
|
BioCardia, Inc. (BCDA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/11/2023 |
8-K
| Quarterly results |
| 08/21/2023 |
8-K
| Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 Interactive Data |
| 08/18/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 08/18/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 08/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/14/2023 |
4
| Altman Peter (President and CEO) has filed a Form 4 on BioCardia, Inc.|
Txns:
| Granted 4,500 shares
@ $0.884, valued at
$4k
|
|
| 08/09/2023 |
8-K
| Quarterly results |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
SC 13G
| SATTERFIELD THOMAS A JR reports a 5.6% stake in BioCardia, Inc. |
| 07/24/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/30/2023 |
8-K
| Termination of a Material Definitive Agreement, Other Events Interactive Data |
| 06/08/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/02/2023 |
4
| GILLIS EDWARD M (Senior Vice President, Devices) has filed a Form 4 on BioCardia, Inc.|
Txns:
| Paid exercise price by delivering 15,512 shares
@ $1.77, valued at
$27.5k
|
|
| 06/02/2023 |
4
| McClung David (CFO) has filed a Form 4 on BioCardia, Inc.|
Txns:
| Paid exercise price by delivering 20,676 shares
@ $1.77, valued at
$36.6k
|
|
| 06/02/2023 |
4
| Altman Peter (President and CEO) has filed a Form 4 on BioCardia, Inc.|
Txns:
| Paid exercise price by delivering 36,821 shares
@ $1.77, valued at
$65.2k
|
|
| 05/30/2023 |
4
| Altman Peter (President and CEO) has filed a Form 4 on BioCardia, Inc.|
Txns:
| Bought 6,200 shares
@ $1.6, valued at
$9.9k
|
|
| 05/22/2023 |
4
| GILLIS EDWARD M (Senior Vice President, Devices) has filed a Form 4 on BioCardia, Inc.|
Txns:
| Granted 40,490 shares
@ $1.7, valued at
$68.8k
Granted 43,803 options to buy
@ $1.7, valued at
$74.5k
|
|
| 05/22/2023 |
4
| McClung David (CFO) has filed a Form 4 on BioCardia, Inc.|
Txns:
| Granted 61,389 shares
@ $1.7, valued at
$104.4k
Granted 68,265 options to buy
@ $1.7, valued at
$116.1k
|
|
| 05/22/2023 |
4
| Altman Peter (President and CEO) has filed a Form 4 on BioCardia, Inc.|
Txns:
| Granted 109,324 shares
@ $1.7, valued at
$185.9k
Granted 159,723 options to buy
@ $1.7, valued at
$271.5k
|
|
| 05/12/2023 |
4
| ZSEBO KRISZTINA M (Director) has filed a Form 4 on BioCardia, Inc.|
Txns:
| Granted 31,085 options to buy
@ $1.49, valued at
$46.3k
|
|
| 05/10/2023 |
8-K
| Quarterly results |
| 05/09/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive Mesenchymal Stem Cells for Therapeutic Applications SUNNYVALE, Calif. – – BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted Patent Number 11,642,377: titled, “ Bone Marrow Derived Neurokinin-1 Receptor Positive Mesenchymal Stem Cells for Therapeutic Applications”, with a patent term that will expire in 2039. The patent specification details methods for selecting and expanding NK1R+ Mesenchymal Stem Cells and their use to treat a number of diseases. The first allowed claim protects using these cells to treat cardiovascular disease, pain, rheumatoid ..." |
|
| 05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 05/01/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 04/14/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/04/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies SUNNYVALE, Calif. – – BioCardia ® , Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery of its investigational autologous and allogeneic cell therapies. The United States Patent Office issued BioCardia Patent Number 11,716,859, entitled “Multi-Directional Steerable Catheter,” with a patent term that will expire in 2035. The patent claims a fundamental design for steerable introducer sheaths, such as those used for BioCardia’s autologous and allogeneic cell therapy procedures, and for transseptal procedures for th..." |
|
| 03/29/2023 |
8-K
| Quarterly results |
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/06/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2023 |
8-K
| Quarterly results |
|
|
|